1627
www.onkologiecs.cz3408043010765133201214262311348396415464514532576617652669709748
/39158043010732
Onkologie.39928043010760109147194214262312331375389
2023;17(4):273-2814401804301074487128172186224261281322344358403444487515553596636
/50828043010732
ONKOLOGIE51598043010761121167227270330389410453
28156558026012657115169
PŘEHLEDOVÉ4549207012660124182256312369444520587645
ČLÁNKY5216207012660115187259327395
Moderní382336501065292132164200242259
přístup40983650106326885118150192227
k4340365010634
léčbě43893650106296296133165
chronické457036501063273109149191208243279311
lymfocytární489736501062961115146187222261295331367408426
leukemie533836501062962102138170225242274
mia:3405540835873106118
a47955408332
multivariate5325540835896112134150183217238254286309343
analysis8965540833270103119151178193220
from1137554083184179138
the1295554083226197
randomized1412554083215593133172231246275310350
GCLLSG17835540834485117150185229
CLL83406540834071103138
trial.49465408321435890106119
J62865408324
Clin667654083405670108
Oncol.7916540834785117154170183
2012;30(9):980-988.9906540833468100130142177211231263281293328363399423458492528541
20.340753085367287
Fischer447754083324773106144179200
K,6667540833550
Bahlo7367540833568106121159
J,9157540832436
Fink971754083324785115
AM,11067540834196110
et12357540833457
al.1311754083324760
Long-term13917540833169107146168191225246304
remissions17157540832054112128154180195233271298
after340854083325278112134
FCR4958540833375111
chemoimmunotherapy6278540833271107166205221281340378417456479518554576610650682
in13308540831554
previously1405854083406297130146185224251267300
untreated1726854083387799121156189211246286
patients340954083397293109143181203231
with591954083506688127
CLL:7389540834071103117
updated8759540833776116148170204243
results1138954083215582119135157185
of13439540833756
the1419954083226095
CLL815349540834072104139
trial.169395408322435991106119
Blood.1832954083355189128167181
2016;127(2):208-215.34010540833468100131143174204236253287305317352386421444475506536548
21.3401153085367082
Fischer4351154083324773106144179200
K,64811540833549
Cramer7111154083396093151186208
P,93211540833539
Busch98411540833674100132170
R,116711540833650
et123011540833456
al.12991154083324760
Bendamustine137211540833671109148180238276302325340378413
in179811540831553
combination1864115408331681263401254083395594127149165203243
with6041254083516790129
rituximab754125408321376098130146205238278
for10531254083185779
previously11531254083396196129145184223249265297
untreated14711254083387799121156188210245285
patients17771254083397395111146185207235
with3401354083516689127
chronic4871354083316991128166181213
lymphocytic72113540831446105144183221254287312327359
leukemia:11011354083144987117151209224256269
a1390135408332
multicenter144213540835795110133148180214252273307328
phase179113540833877109136171
II198213540831530
trial340145408322435991107
of46814540833757
the5451454083226096
German66114540834480101160193231
Chronic91314540834078100137176191223
Lymphocytic115714540833160119159197236269303328343376
Leukemia155314540833266104135169227243275
Study18481454083335493132164
Group.34015540834465103141180192
J548155408324
Clin5871554083405570108
Oncol.71015540834786118155171184
2012;30(26):3209-3216.90915540833468100130143178212232266299317329364397431466490522555586617630
22.3401653085367288
Eichhorst4481654083334779117155194215243266
B,73316540833648
Fink8011654083324785115
AM,93516540834197110
Bahlo106516540833568106121160
J,124416540832436
et130016540833356
al.13751654083324760
First-line1455165408332476895118138154169207242
chemoimmunotherapy17171654083316910416220021627334017540835795133171193231266288321360391
with7451754083516689127
bendamustine88617540833974112151184241279305329344382417
and131717540833270109
rituximab1440175408320365996128143201233273
versus17271754083316687114151178
fludarabine,191917540831734713401854083387090123162177215249261
cyclophosphamide,6131854083316495110148187225263289328366398455470508543554
and118018540833269108
rituximab1300185408321365896127142199231270
in158218540831552
patients16471854083387192107141179200227
with18871854083506588125
advanced34019540833271104136174207240280
chronic6361954083316990128166181213
lymphocytic86519540831547106145183222254288313328360
leukaemia12411954083155088118151186244259291
(CLL10):15481954083195890122152183201213
an177819540833169
international,186419540831452741081293402054083387092108146185218233246
open-label,60720540833777113152174191223263299315327
randomised,9552054083215493132171229245271306346359
phase133520540833978110137173
3,152820540833547
non-inferiority159620540833776115138154192211246268284322344360382416
trial.340215408322435991106119
Lancet47421540833265103135169191
Oncol.68121540834785117154170183
2016;17(7):928-942.87921540833569101132144174203220254274286321354388411446481514526
23.3402253085367287
Kutsch4402254083357294122154192
N,64522540834457
Bahlo71522540833568106121159
J,88722540832436
Robrecht93622540833574113135168201239260
S,120922540833345
et126722540833456
al.13362254083324760
Long140922540833168107146
Term15672254083336485143
Follow-up17232254083326985100138189211250289
Data3402354083457899132
and48623540833270109
Health-Related60823540834479111127149187210247282297330351385425
Quality104623540834786118133148171204
of126423540833757
Life13342354083324766101
in144923540831452
Frontline15152354083325289128149165180217252
Therapy178123540833372107128161200232
of34024540833757
Fit4122454083324770
Patients4972454083356789104139177198226
Treated7382454083335084116138172211
With9642454083587496135
FCR111424540833272108
Versus12372454083366990117154181
BR143324540833571
(CLL1015202454083185889121151182
Trial1718245408332496597112
of184624540833756
the19182454083215994
GCLLSG).34025540834484116148182227245256
Hemasphere.61225540834479137169195234273308329363375
2020;4(1):e336.100325540833468101135148183202234248260294329362396410
24.3402653085367186
Goede44726540834483118158193
V,66126540833544
Fischer7262654083324774106144179201
K,94726540833550
Busch10182654083357399132170
R,120826540833650
et127926540833456
al.13562654083314760
Obinutuzumab143726540834787102140178201239268307365397437
plus18942654083395593119
chlorambucil3402754083317085124146179238277316349364379
in74027540831553
patients8142754083397294110145183205233
with10682754083516789128
CLL121727540834072104
and134227540833271110
coexisting147327540833169104136152179202218256295
conditions.17892754083326910814716318520134028540833776102116
N471285408345
Engl53128540833370109125
J671285408324
Med.71028540835590130143
2014;370(12):1101-1110.86828540833468100131143178210243263294324342354384412443475493524552580611624
25.3402953085367387
Goede44829540834483118158193
V,66229540833544
Fischer7272954083324773106144179200
K,94829540833550
Engelke101829540833371110145161191225
A,126329540834156
et133929540833457
al.14162954083324860
Obinutuzumab149729540834787103141178201239269307365398437
as195429540833259
frontline3403054083184078116138153168206241
treatment5943054083224377109131189224262284
of89130540833757
chronic9613054083316990127166181213
lymphocytic118730540831547105144183221254287312327359
leukemia:15603054083144987117151209224256269
updated1842305408337761161483403154083215492
results4443154083215480116131152179
of63531540833755
the7023154083215892
CLL1180631540834070101130157
study.9753154083264885123154163
Leukemia.115031540833164101130163220234265278
2015;29(7):1602-1604.14403154083336697126137171204222256274286315345379411431461491525561572
26.3403253085367187
Mulligan44632540835492108123138176209247
SP,7113254083336872
Gill802325408344597489
DS,9103254083457891
Turner10193254083336687126161182
P,122032540833540
et127832540833456
al.13533254083324760
A1432325408341
Randomised149132540833668106146184242257283318358
Dose186732540834684111146
De-Escalation34033540834580102136163195227243274296310348386
Safety7383354083326583117139172
Study9233354083325390129160
of109633540833755
Oral116433540834768100115
Fludarabine,12923354083324683122154174207245261298332344
{+/-}Oral16493354083185881100118166188220235
Cyclophosphamide189733540833966973403454083155290128165191228266297354368406440
and79234540833168106
Intravenous910345408314517293125155189226263300325
Rituximab12473454083355071108139154210241279
(OFOCIR)15383454083196496142182196231249
As179934540834168
First-1878345408332476793116134
-Line3403554083215469107142
Therapy49535540833272106128161200231
of73935540833756
Fit8083554083324770
Patients8913554083356788104138176198225
with11293554083516689127
Chronic12693554083407798135174189221
Lymphocytic150335540833159118157195234266300324340371
Leukaemia1887355408332661033403654083306398156171203
(CLL)5603654083195889121141
Aged71836540834179114153
>=6588936540834183120154
Years10603654083356698119146
-1223365408321
End126136540833371110
of138836540833757
Recruitment146236540833570103124162177200258293331353
Analysis1832365408341791111271583403754083264167
of42637540833756
Response5013754083367197136175214240275
and79537540833270109
Toxicity9233754083326696112144159181215
of115737540833757
the12323754083226095
Australasian134637540834178104127149182197229256271303341
Leukaemia170637540833165103133167201259274306
and34038540833270109
Lymphoma46738540833160118157196234292325
Group81038540834365102140179
(ALLG)10073854083196092124166185
and121038540833270109
CLL133738540833971103
Australian145838540834178104127149182197212244282
Research17583854083357097132164185216254
Consortium34039540834077115142180202226241279337
(CLLARC)6913954083185789121164200241261
CLL596639540834072104140
Study.11203954083325391130162172
ASH130639540834175119
Annual143939540834179117155187202
Meeting165539540835590125147163201240
Abstracts.1909395408341803404054083264971104136160188201
2012;120(21):436.55740540833468100130142172202236256289321335347382414449462
27.3404153085367079
Smolej43241540833289127143178193
L,63741540833145
Brychtova6954154083355690121158180216248281
Y,98841540833543
Cmunt104441540834097134172193
E,125041540833245
et130841540833456
al.13764154083324760
Low-dose144941540833168118140181218245280
fludarabine1741415408317347111014216319523425034042540833873
and42742540833270109
cyclophosphamide5504254083326597112150190228266293332371403461476515550
combined111442540833168126166181219254294
with14224254083516689127
rituximab1563425408321375997128144202234273
in185142540831452
the19184254083215994
first-line340435408317335481103122138153190224
treatment5764354083224276107128185220257278
of86643540833756
elderly/comorbid9344354083344987121142157188211239275332370391430445483
patients14294354083387192107141178199226
with16674354083506587125
chronic18044354083316889125163177209
lymphocytic34044540831546104143181219251284309324355
leukaemia/small7084454083144986116149183241256287313337394426441456
lymphocytic117744540831446104142180218251284308323355
lymphoma154444540831546104143181219277309
(CLL/18654454083185788120147
SLL):3404554083326394113124
long-term4774554083145289128150172205225283
results7724554083215481117132154181
of96645540833655
project10344554083385996111145177201
Q-lite12474554083467085100122155
by141545540833868
the14964554083215993
Czech160145540834070103136173
CLL178645540834071102
Study1900455408333539034046540833870
Group.42546540834466103141180193
Br63346540833557
J705465408324
Haematol.74446540834577112170202224261277290
2021;193(4):769-778.104946540833468101133141171201234252285302314348379413437468503536550
28.3404753085367288
Burger4454754083357394133167189
JA.6504754083246479
Inhibiting7454754083155391106145161183198236275
B-cell10374754083355892125141156
receptor12094754083215588121161183220241
signaling14674754083264179117150165180218257
pathways17404754083397294132182215246273
in34048540831553
chronic4124854083316990127166181213
lymphocytic64448540831547106145183222254288313328360
leukemia.10234854083155088118152210225257270
Curr13134854083407697119
Hematol145148540834479137170191228244
Malig171548540835487102117156
Rep.189048540833671110122
2012;7(1):26-33.34049540833468100130142175192223238250285318342374407420
29.3405053085367285
Byrd4465054083356789128
JC,5945054083246578
Brown6925054083355794145183
JR,8965054083246074
O’Brien9905054083476097118134168206
S,121750540833245
et128250540833456
al.13585054083324760
Ibrutinib14395054083145375113136151189204243
versus17025054083326688115152178
ofatumumab1900505408338579034051540832260117155213245284
in63851540831552
previously7045154083396094127142180218245260292
treated10095154083224377109131165204
chronic12275154083316990127166181213
lymphoid145351540831547106145183221237276
leukemia.17425154083155088118152210225257270
N340525408345
Engl40052540833370109125
J540525408324
Med.58052540835489129142
2014;371(3):213-223.73752540833468100131143178210243258291308320355387417439470504539552
30.3405353085367286
Munir44353540835492129143164
T,62453540833240
Brown6815354083365693143181
JR,8795354083245973
O’Brien9685354083476096116131165203
S,118853540833244
et124953540833455
al.13215354083324759
Final13975354083324684115130
analysis154453540833269101115146173187212
from17735354083184076134
RESONATE:19245354083356834054540833279124165193227239
Up59554540834482
to69454540832158
six7685454083264070
years8555454083316495116142
of101454540833756
follow-up1086545408318557085122172194232271
on137354540833775
ibrutinib14645454083155374112134148185200238
in171854540831552
patients17875454083387092106140178198225
with3405554083506486123
previously4745554083385891122137173210235249280
treated7655554083214174105125158196
chronic9725554083316787123160174205
lymphocytic118855540831445102140177214245277301315346
leukemia15455554083144884113146202216247
or180355540833757
small187155540832682113127141
lymphocytic34056540831545102140177214246278301316346
lymphoma.69756540831546103140178215271302315
Am102356540834097
J1131565408323
Hematol.116556540834478134165186222236248
2019;94(12):1353-1363.14245654083346797126138172207225255284301312340369401432453483511544577588
31.3405753085366982
Burger4435754083357495133168190
JA,6535754083256579
Tedeschi75357540833263103138165197236251
A,102457540834256
Barr11005754083366990112
PM,123357540833589103
et135657540833457
al.14335754083324861
Ibrutinib15145754083155576115138153191206246
as178057540833259
Initial1859575408315536991107139154
Therapy34058540833372107129162201233
for5935854083195678
Patients6925854083356789104139177199227
with9395854083516789128
Chronic108758540834078100137176191223
Lymphocytic133058540833261119159197236269302327343375
Leukemia.172558540833266104134169227242274288
N340595408345
Engl40059540833370109125
J540595408324
Med.58059540835489129142
2015;373(25):2425-2437.73759540833468100130141176208242260294329347359394426459494516547579611643649
32.3406053085377389
Woyach45160540835996129163196235
JA,7086054083246680
Ruppert81060540833675115156193215241
AS,10726054083427790
Heerema118460540834581118140175235268
NA,147460540834588103
et159860540833558
al.16776054083334962
Ibrutinib17616054083155578117141157196212252
Regimens34061540833570110125183218256282
versus6436154083316587114151177
Chemoimmunotherapy84161540834078113171209224282340377415454476514549570603642674
in153561540831552
Older160861540834763102137158
Patients17866154083356789104139177199226
with3406254083516689127
Untreated48262540834482103125159191212246286
CLL.78362540834071103117
N915625408345
Engl97562540833371110125
J1115625408325
Med.115562540835489129142
2018;379(26):2517-2528.131262540833569100131144179211244263297331349361396431462491510541576609642656
33.3406353085367186
Shanafelt43963540833270103141173192226242264
TD,7166354083338091
Wang82063540835789127166
XV,9996354083387685
Kay109763540833569100
NE,12106354083447791
et131463540833456
al.13836354083324760
Ibrutinib-Rituximab14566354083155476114136152190205244267304320342380412427485517556
or34064540833759
Chemoimmunotherapy41464540834078113171209225282340378416454476514549570603643674
for11036454083195678
Chronic11966454083407899137175190222
Lymphocytic143364540833260119158197235268301326341373
Leukemia.18226454083316510313316734065540835772104118
N473655408345
Engl53365540833370109125
J673655408324
Med.71365540835489129142
2019;381(5):432-443.87065540833468100130143178213244260293311323358390423443480517549562
34.3406653085367185
Shanafelt43766540833269100136167185218233254
TD,7026654083327787
Wang80066540835787124161
XV,9726654083387583
Hanson106666540834475111136173210
CA,12876654083408194
et139266540833455
al.14586654083314557
Long-term152666540833167104142163184217237294
outcomes1831665408336739512416034067540835690115
for4666754083185474
ibrutinib-rituximab5516754083145272109130144180194231253274288309346375390445476514
and107667540833167105
chemoimmunotherapy119167540833167101157193208263319355392428449485519539570608637
in183967540831451
CLL:190067540834070100113
updated34068540833776114146167200239
results5936854083215480117131153180
of78768540833756
the8576854083215993
E19129646854083336393124153
trial.1131685408322435889104116
Blood.12616854083355087126164177
2022;140(2):112-120.14526854083346799134145175205240259292309321350377406426456485518530
35.3406953085356982
Mato43369540835485105140
AR,5846954083407587
Nabhan68269540834475112149180216
C,90969540833951
Thompson97169540833269106162200225262299
MC,128069540835493105
et139569540833455
al.14606954083324658
Toxicities15286954083326594108138152173187220246
and178469540833268105
outcomes1900695408337739434070540833167124159185
of53670540833756
6216037054083346797
ibrutinib-treated7127054083145273111132147184198236259280301334365386419457
chronic11817054083316888125162177208
lymphocytic140070540831546103142179217248281305320351
leukemia17627054083154986115148205219250
patients3407154083397192107141178199226
in58071540831552
the6477154083215993
United7547154083448196117151189
States:9587154083325385106139165177
a1149715408332
real-world1196715408320548599121172209230245283
analysis.149471540833269101115146173187212225
Haematologica;1734715408344751091671982192563407254083155290104135167178
2018;103(5):874-879.5297254083346697127138167197229246279296307341372402423458490522532
doi:10727254083387589100
10.3324/haematol.2017.182907.11847254083336475110141173203227265296330386418438474489501536568599627632662692724757792823828
Epub34073540833371108147
20185017354083346798129
Feb64473540833265104
1.76273540833443
PMID:81873540833689103148161
29419429;99373540833467102132162197229262274
PMCID:128173540833588128142187200
PMC5927982.149573540833588128163194227259292326359371
36.3407453085367288
Paydas4437454083356798136169195
S.65374540833346
Management71474540835587125158197232290325363384
of111474540833756
adverse118574540833271104138159187222
effects/toxicity14227454083345473107140164191217240277307322354370392426
of186374540833757
ibrutinib.193574540831554340755408321598197135150189201
Crit557755408340617699
Rev67175540833570103
Oncol78975540834786118155171
Hematol.97575540834479137169191228244257
2019;136:56-63.124775540833468100130143173203238250285320343380414427
37.3407653085367181
Lasica4427654083326693108141174
M,63776540835569
Tam72776540833361120
CS.8687654083417589
Management97876540835588127159199235294329368390
of138976540833857
Ibrutinib14677654083155577116139155193209249
Toxicities:17367654083336899115147163186201237264277
a340775408332
Practical3847754083355588119143158189222237
Guide.6337754083448196134169181
Curr8267754083407697118
Hematol95677540834479136168189226241
Malig121077540835486101115154
Rep.137677540833570108121
2020;15(3):177-186.150977540833467100133146176205223256273284313342376395425456490503
38.2140553085367287
Stephens2240554083325386125163198236262
DM,251455408345100113
Byrd2640554083356788126
JC.2779554083246477
How28695540834482132
I301455408315
manage30415540835789127159198232
ibrutinib3286554083145374112134150187202241
intolerance353955408315527311012616018121425121406540833165
and22216540833270109
complications23476540833168126165181196228261283298336374401
in27646540831553
patients2833654083397294109144182203231
with3080654083516689127
chronic3224654083316990127166181213
lymphocytic34536540831547105144183221254287312327359
leukemia.2140754083155087118152210225257270
Blood.2425754083365190128168181
2019;133(12):1298-1307.26217540833569100131143174203236254286316334346376406440475497528558593625631
39.2140853085367185
Burger2238854083357394132167188
JA,2439854083256579
Barr2531854083356889111
PM,26558540833589102
Robak27708540833574113146176
T,29598540833342
et30148540833456
al.3083854083324760
Long-term31568540833169107146168191224245304
efficacy347385408334527088120153185218
and37048540833270109
safety2140954083265978113135169
of23249540833857
first-line239695408317345583106125142157195230
ibrutinib2641954083155475114136152189205244
treatment2900954083224377109131189224262284
for3199954083195678
patients3293954083387193108143181203230
with3539954083506688127
CLL/36819540834072104131
SLL:21401054083326495109
52264105408335
years23141054083316597118145
of247510540833756
follow-up2546105408319567287125177199238277
from28381054083184078136
the29891054083226095
phase309910540833977110136171
33286105408334
RESONATE-2333510540833569103150196237266300322353
study.3703105408326498721401154083387080
Leukemia.223511540833266104134168226241273286
2020;34(3):787-798.253711540833468101135148183218238271288300333367400418450483518532
40.21401253085367489
Seymour22481254083326899158196234255
JF,25221254083255864
Byrd26051254083356789127
JC,27511254083256678
Ghia28491254083438297129
P,299712540833540
et305612540833456
al.31311254083324861
Detailed321112540834580103135151166201240
safety34701254083266079113135169
profile36581254083396098115132214013540831550
of221113540833858
acalabrutinib22901354083326498114146186208247270286324340379
vs269013540833260
ibrutinib27711354083145476115138154192208247
in303913540831553
previously31131354083396196129145184222249265297
treated34311354083224478111133167207
chronic3659135408332709213021401454083385487
lymphocytic224814540831548108149188228261296322337370
leukemia26401454083155190121156215231264
in292514540831554
the30011454083226197
ELEVATE-RR311914540833466100139179209244266304342
trial.3482145408322446093109123
Blood.36261454083365392132173186
2023;142(8):687-699.214015540833468101136147177208241258292310322357393426444482516551562
41.21401653085366881
Burger22341654083357394132167188
JA,24351654083246478
Sivina2526165408332477995133165
M,270416540835467
Jain27841654083245671109
N,290616540834558
et297616540833456
al.30451654083324760
Randomized311816540833568106145183241256285319358
trial3489165408322435991106
of360816540833756
ibrutinib367716540831554751132140175408322377489128
vs228017540833259
ibrutinib23511754083155375113135150188203241
plus26051754083385491117
rituximab2735175408320365896127142199231270
in301817540831452
patients30821754083397293108143180202229
with33241754083506587125
chronic34621754083316989126164179211
lymphocytic368617540831446104214018540833977115148182206222254
leukemia.24091854083155087118152210225257270
Blood.26941854083365190128168181
2019;133(10):1011-1019.289018540833569100131143173203236254286318336348378409441469487518550581611622
42.21401953085367086
Kater22441954083356890124145
AP,24071954083417781
Owen250619540834799134172
C,269619540833952
Moreno276619540835593115149187225
C,300919540834053
et308019540833456
al.31541954083314760
Fixed-Duration32321954083324778112151174221259280313335350388427
Ibrutinib-Venetoclax367719540831453751132140205408322377590129152188221259294316353386401433465
in261920540831452
Patients26852054083356789104139177198226
with29252054083506688127
Chronic30652054083407899136175190222
Lymphocytic330120540833159118157196234267300325340372
Leukemia368720540833165103214021540833064122137169
and232421540833270109
Comorbidities.244821540834077135174195235251289305327342377404417
NEJM288121540834478104159
Evid.30562154083326480119132
2022;1(7).320321540833468101136148178193228248258
43.21402253085367186
Danilov224022540834578116131146184216
AV,24702254083417483
Persky25662254083366990117147181
DO.276122540834594105
Incorporating28802254083155385122143183222243276298314351390
acalabrutinib,32842254083326497112144184205244266281319334373385
a3683225408332
selective37292254083266121402354083154982105120153186
next-generation233923540833772103127147187221259294314347369384421459
Bruton28112354083355694116153191
tyrosine30142354083225577114140155192227
kinase32542354083294583115141175
inhibitor,34422354083155290104143158181217238248
into37032354083145273110
clinical2140245408331476199114146179195
practice23512454083386093125149164196230
for25972454083185677
the26902454083226095
treatment28012454083224377109131189224262284
of310124540833756
haematological317324540833770105163195217254270308347362394427443
malignancies.363124540835890106121159214025540833870108140155190217230
Br238625540833556
J2458255408324
Haematol.249725540834477111169202223260276289
2021;193(1):15-25.280225540833468101132140170201233252283298310339369391422457469
44.21402653085367490
Thompson224926540833372110168208234273311
PA,25792654083357387
Burger26852654083357394132167189
JA.28932654083246479
Bruton’s29912654083355695117154193205230
tyrosine32402654083225577114141156194229
kinase34882654083304684116143178
inhibitors:3685265408315539110621402754083395477114135162175
first2332275408317335482105
and245427540833169108
second25792754083266194131169208
generation280427540833873111146167200222237275314
agents313427540833271106144166193
for33442754083185678
patients34382754083397294109144182203231
with36862754083506688126
Chronic21402854083407899136175190222
Lymphocytic237928540833260119158196235267301326341373
Leukemia276928540833266104134168226241273
(CLL).30592854083195890122141152
Expert322828540833366105141162186
Opin343228540834787102140
Investig35902854083155384118145168183222
Drugs.214029540834567105144170184
2018;27(1):31-42.233929540833569100131144179212228260274286321352371407440452
45.21403053085367085
Ghia22373054083438196127
P,237630540833539
Pluta24283054083354986108140
A,258030540834154
Wach264730540835687119156
M,281530540835467
et289530540833355
al.29623054083324759
ASCEND:303430540834073113145189235247
Phase329430540833471103129163
III,3469305408315304557
Randomized353830540833567105143181238253214031540832862102
Trial2258315408333506698113
of238831540833756
Acalabrutinib246131540834172105120153192213252274289327342382
Versus28593154083366890117154180
Idelalisib30563154083155489104136152167193208247
Plus33193154083355088114
Rituximab34503154083355073111142158215248287
or375331540833859
Bendamustine214032540833569106144175231268293316330367401
Plus25533254083344885110
Rituximab26753254083355071108139153210241279
in296632540831451
Relapsed30293254083356984115153179213251
or329232540833757
Refractory33613254083356987109141172195231252285
Chronic3658325408339759613221403354083385385
Lymphocytic224433540833160118157196234267300325341373
Leukemia.263633540833165103133167225241273286
J2941335408324
Clin29853354083405570108
Oncol.311233540834786118155171184
2020;38(25):28492861.331533540833468101135148183217237270305324336371404441474214034540833468103133143
46.21403553085367389
Sharman224235540833270102123181214251
JP,25063554083246064
Egyed258335540833371103137176
M,277235540835468
Jurczak28533554083246182113144177207
W,307335540835767
et315235540833456
al.32213554083324760
Acalabrutinib329435540834172105120152191212251273288326341380
with36873554083506588126
or214036540833759
without22173654083516689127165203226
obinutuzumab24613654083387793131168191229258296354386426
versus29053654083326687115152178
chlorambucil31023654083316984122144177235274312344359375
and349536540833270109
obinutuzmab3622365408338779313116821403754083225989147179218
for23713754083185577
treatment-naive24613754083214377108130188223261282301340372387420454
chronic29283754083316989127165180212
lymphocytic315237540831547105144182221253286311326358
leukaemia35233754083154987117150185243258289
(ELEVATE21403854083185182115152191219253
TN):24063854083327897108
a2527385408332
randomised,25713854083215491130168226240266301340353
controlled,293638540833168106127148185201216250290302
phase325138540833876108135169
33433385408334
trial.3480385408321425889105117
Lancet.361038540833164102134167189202
2020;395(10232):1278-1291.214039540833468101135148183216251268300331364399431449461491521554587610641671705737746
47.21404053085367079
Byrd22324054083356789128
JC,23734054083246578
Hillmen2464405408344597489147182220
P,269740540833540
Ghia27504054083448297129
P,289340540833539
et294540540833457
al.30154054083314760
Acalabrutinib308840540834172105121153192214252274290328343382
Versus34834054083356889117154180
Ibrutinib367640540831554761142140415408322377590129
in228841540831552
Previously23594154083365690123138176214241256288
Treated26664154083324983115137171210
Chronic28954154083407899136175190222
Lymphocytic313641540833160118157196234267300325341373
Leukemia:352841540833165103133167225240272284
Results21404254083357097134150172200
of235942540833756
the24344254083226095
First2548425408333486996119
Randomized268642540833568106145183242257286320360
Phase306542540833572104131166
III32504254083153045
Trial.3314425408333506698113126
J3459425408324
Clin35024254083405570108
Oncol.362942540834786118155171184
2021;39(31):3441-3452.214043540833468101133141176209228262293307319354390427457476508544576609622
48.21404453085367389
Brown22424454083355693144182
JR,24374454083245973
Eichhorst25234454083324778116154191213240263
B,279844540833548
Hillmen2858445408344597489146181219
P,308944540833540
et314144540833456
al.32104454083314659
Zanubrutinib328244540833770107145183205243265280317332371
or366644540833758
Ibrutinib3737445408314532140455408321598197135150189
in234345540831553
Relapsed24104554083357086118157184219259
or268345540833759
Refractory27564554083367190112145177201238260294
Chronic30644554083407899136175190222
Lymphocytic330045540833160118157196234267300325341373
Leukemia.368745540833165103214046540833064122137169182
N2337465408345
Engl239746540833371110125
J2537465408325
Med.257746540835489129142
2023;388(4):319-332.273446540833569102136148183217253272305322334369400430454486519552564
49.21404753085367285
Furman22404754083326990148181219
RR,24744754083357185
Sharman257447540833371103124183215253
JP,28424754083246064
Coutre292147540834077115138159194
SE,31304754083326477
et322247540833457
al.32944754083314760
Idelalisib33694754083145388104136152166193207247
and363147540833169108
rituximab37544754083213721404854083226091106164196236
in239448540831553
relapsed24654854083215571103142169204243
chronic27274854083316990127166181213
lymphocytic295848540831547105145183221254288312328360
leukemia.33364854083155087118152210225257270
N3625485408344
Engl368848540833270109124
J2140495408324
Med.217949540835590130143
2014;370(11):997-1007.233749540833468100131143178210243263294322336348383419452470501533569601607
50.21405053085367287
Flinn22475054083324762100138
IW,24045054083157383
Hillmen2506505408345607590148183221
P,274650540833540
Montillo280550540835593132153169184199237
M,306250540835467
et314950540833456
al.32255054083324760
The330450540833372107
phase343150540833877109136171
33621505408334
DUO367550540834590138
trial:2140515408321425788103115
duvelisib226751540833774105139154168194208246
vs252551540833157
ofatumumab25945154083375688109146203239296327366
in297251540831451
relapsed30355154083205469100138164198237
and328451540833168106
refractory3402515408320547294126157180216237270
CLL/368451540834070101128
SLL.21405254083326495109
Blood.22655254083355189127167180
2018;132(23):2446-2455.246052540833569100132144174204236254288322339351387418455491515546578611643655
51.21405353085377285
Sharman224753540833373107129190223263
JP,25325354083256267
Coutre262153540834180119143166201
SE,28445354083336781
Furman29475354083337193154188228
RR,31965354083377590
et330753540833559
al.33885354083324962
Final34725354083344989123139
Results363353540833673101140156214054540832251
of221254540833858
a2291545408333
Randomized,234554540833670109149188248263293328369382
Phase274954540833574107134170
III29415454083153146
Study30095454083335594134167
of319754540833858
Rituximab32765454083365276115147163222255296
With35935454083587598138
or375254540833860
Without21405554083577496134172211233
Idelalisib23925554083145388104136152167193207247
Followed26575554083327086101139190224264
by294055540833869
Open-Label302855540834787122160183216249289324340
Idelalisib33865554083155489105137152167193208247
in365255540831452
Patients37235554083356721405654083223772110131159
With23145654083587496135
Relapsed24645654083357086118157184219259
Chronic27385654083407899136175190222
Lymphocytic297556540833260119158196235267301326341373
Leukemia.336456540833165103133167225240272285
J3665565408324
Clin37055654083395570108
Oncol.214057540834786118155171184
2019;37(16):1391-1402.233957540833468100130143178210226258289307319349379412444463494525561594606
52.21405853085367085
Spacek223858540833270103134167197
M,244858540835467
Smolej252758540833289127142176191
L,273158540833144
Simkovic278758540833347104134170202217249
M,304858540835467
et312758540833456
al.31955854083324759
Idelalisib32675854083145387102134149163189204242
plus35215854083395491117
rituximab3650585408321365895126141214059540835790129
versus22825954083316687114151177
ibrutinib24725954083155476114136152189205244
in272959540831452
the27945954083226095
treatment29025954083214377109130188223261283
of319859540833756
relapsed/refractory32675954083215571103142169204243269289323342364397429453490512546
chronic21406054083316990128166181213
lymphocytic237260540831546105144183221254287312327359
leukaemia:27506054083155087118151186244259291303
A3072605408341
real-world31326054083205486102124176213235251290
analysis344060540833270103118150177192218
from36766054083194178136
the21406154083226095
Chronic22486154083407899136175190222
Lymphocytic248361540833159118157196234267300325340372
Leukemia286861540833266104134168226241273
Patients31546154083356789104139177199226
Registry339361540833671110125152175196230
(CLLEAR).3636615408319589012215521406254083417796107
Br226262540833557
J2334625408324
Haematol.237362540834577112170202224261277290
2023;202(1):40-47.267862540833468101136147182216249266298313324359395419455487494
53.21406353085367186
Ryan223963540833568101139
CE,23916354083407386
Davids249063540834678109125164190
MS.269463540835487100
BCL-2280863540833576107122153
Inhibitors,29746354083155391106145161183220242269282
Present32696354083365690117152190212
and349463540833270109
Future.36166354083326991129150184197
Cancer214064540834073111143177198
J.235364540832437
2019;25(6):401-409.240564540833468100130143178213231264282294328364396415451487522533
54.21406553085367389
Stilgenbauer2250655408333546985124159197237270308343364
S,263565540833346
Eichhorst27016554083334880118157195217244268
B,298965540833649
Schetelig305865540833366104139161195211226265
J,334465540832436
et340165540833457
al.34786554083324861
Venetoclax35596554083366910814316520223521406654083154779
in223366540831452
relapsed22996654083215571103142169204243
or255666540833759
refractory2629665408321557496129161185222244278
chronic29216654083316990127166181213
lymphocytic314866540831547105144183221254287312327359
leukaemia35216654083155088118151186244259291
with21406754083516689127
17p228267540833564101
deletion:23996754083387288123145161198237249
a2664675408332
multicentre,271167540835895111133148180214252273295329341
open-label,306867540833776112150173189221260296311324
phase340767540833978110136171
23594675408334
study.36446754083264987126158168
Lancet214068540833165103135169191
Oncol.234668540834786118155171184
2016;17(6):768-778.254568540833468100131144174203220253271283316348383406437472505519
55.21406953085367185
Roberts224469540833574113149170195222
AW,248569540834197107
Davids261169540834577109124163190
MS,282069540835487100
Pagel293969540833567106141156
JM,31156954083247992
et322669540833456
al.33016954083324760
Targeting33806954083336182120155177193231270
BCL2366969540833576107143
with21407054083506587124
Venetoclax227770540833567104139160197229244275306
in259570540831552
Relapsed26597054083356985116154181215254
Chronic29257054083397797134171186217
Lymphocytic315570540833158116154192230262295319334365
Leukemia.353270540833165102131165222236268281
N2140715408345
Engl220071540833370109125
J2340715408324
Med.238071540835489129142
2016;374(4):311-322.253771540833468100131144179211241261293311323358389417435468500535547
56.21407253085357186
Cairo22387254083397186106143
MS,23937254083538598
Bishop25037254083354975112149187
M.270372540835367
Tumour278272540833264121158195216
lysis3010725408315467286111
syndrome:31347254083255795133153190247281293
new343972540833771121
therapeutic3572725408321599311314518421821407354083375974105
strategies22587354083264869102123156195210244271
and254173540833269108
classification.26617354083314678104130144162178210242264279316354367
Br304073540833556
J3109735408324
Haematol.314573540834476110167199220257272285
2004;127(1):311.34427354083346810313915018020924225828930331534921407454083346271
57.21407553085367180
Howard223575540834482133166187226
SC,24757554083337386
Jones257675540832463101136163
DP,27547554083458186
Pui28547554083367388
CH.29577554083408497
The306975540833372107
tumor319175540832159117156177
lysis3383755408315477488115
syndrome.35127554083265998137158195254289301
N2140765408345
Engl220076540833370109125
J2340765408324
Med.238076540835489129142
2011;364(19):1844-1854.253776540833468100128136171205242261293323341353383414450487510541572606641654
58.21407753085357085
Gribben22377754083436378116154189225
JG.24747754083246780
Practical25657754083355586117141155186217232
management280877540835788125156193227283317354375
of319477540833755
tumour326077540832258114152188209
lysis3480775408315457185110
syndrome3602775408325579413215218839405540835792
in40445540831553
venetoclax-treated41095540833266103138160197229244276307328350371405437458492531
patients4652554083397293108143180202229
with4894554083506588125
chronic5032554083316990127165180211
lymphocytic52565540831546104143181219252285309325356
leukaemia.3940654083155087118151186244259291304
Br42606540833556
J433265408324
Haematol.43716540834477111169202223260276289
2020;188(6):844-851.46766540833468101135148178209244263296314326361398435458493527558568
59.3940753085367184
Seymour4041754083326799158196234255
JF,4313754083245763
Kipps4392754083355291130157
TJ,4566754083325365
Eichhorst4648754083334779117155194215243266
B,49307540833648
et49957540833456
al.5068754083314760
Venetoclax-Rituximab5144754083366910714216420123424928131333337138640944639408540833046103136175
in41318540831553
Relapsed4200854083357086118157184219259
or44758540833759
Refractory4550854083367190112145177201238260294
Chronic4860854083407899136175190222
Lymphocytic50988540833160118158196234267301325341373
Leukemia.5487854083316610339409540833064122137169182
N413795408345
Engl41979540833371110125
J433795408325
Med.43779540835489129142
2018;378(12):1107-1120.45349540833569101132144179211244263295325343355384412444476495526553583617630
60.39401053085367388
Fischer40441054083324773106144179200
K,426010540833449
Al-Sawaf43251054083415679110143194226245
O,458610540834758
Bahlo466010540833568106122160
J,483610540832436
et488810540833456
al.49601054083314760
Venetoclax503510540833669107142164201234249281313
and536410540833169108
Obinutuzumab54881054083478710339401154083387598136165203261293333
in428711540831452
Patients43531154083356789104139177198226
with45931154083516689127
CLL473411540834071103
and485111540833270109
Coexisting497411540834077112144159185209224262301
Conditions.528911540834077115154169192207245283310323
N3940125408345
Engl400012540833370109125
J4140125408324
Med.418012540835489129142
2019;380(23):2225-2236.433712540833468100130143178212248267301336353365400435470505527558592627662675
61.39401353085367084
Rawstron404813540833570122150175198237276
AC,43481354083418196
Fazi44671354083326394111
C,460213540834054
Agathangelidis467913540834181115138178211251291328345361402418446
A,514813540834157
et522813540833458
al.53091354083324963
A5395135408341
complementary54591354083327013039401454083395693152189228251286308344
role43071454083216077114
of444414540833758
multiparameter452614540835796113137154195229252286346382406441464
flow50141454083183777130
cytometry51671454083326793131191228252275310
and550114540833271112
high-throughput39401554083395698139164189231254295336378419461503528
sequencing449315540832765107148186227262280321363
for48811554083196084
minimal499015540835977118135197232250
residual52651554083215888105147188223241
disease553115540833957394016540832765100129167
detection413416540833977102138174201219260302
in446216540831556
chronic45441654083327497138179197232
lymphocytic480216540831550112155197238274310338356391
leukemia:52191654083155394127164226243278293
an553816540833374
European39401754083347397137180219253294
Research426017540833674104142177200234275
Initiative4561175408315567499116151176193229266
on485217540833980
CLL495817540834175110
study.50941754083275293136170183
Leukemia.530217540833270110143181242260295310
2016;30(4):929-936.394018540833470103135149186221242277296309345380415440477511547561
62.39401953085367187
Kater40461954083356890124145
AP,42101954083417681
Seymour43101954083326799157196234255
JF,45831954083255864
Hillmen4665195408344597590147182220
P,490419540833540
et496219540833457
al.50371954083324760
Fixed51161954083324778112152
Duration528619540834684105138160175213252
of555619540833757
Venetoclax-Rituximab394020540833668106141164201233249281312333370386408446478493551583622
in457620540831553
Relapsed/Refractory46432054083357086118157184219258284321356375397430462487524545579
Chronic52362054083407899136175190222
Lymphocytic547120540833260119394021540833977115148181206221253
Leukemia420521540833266103133167225240272
Eradicates44902154083325386125140171204226259286
Minimal478921540835469107122180212227
Residual50292154083357097111150188220235
Disease52772154083456086121153179214
and550421540833270108
Prolongs39402254083355591107144182220245
Survival:41982254083326889123138170202217229
Post-Treatment44392254083357197119139168185218249270327362399420
Follow-Up4871225408332698499136186208253291
of517422540833755
the52422254083215893
MURANO534722540835497132174218266
Phase394023540833573105131166
III41222354083143045
Study.41822354083335492131163173
J4370235408324
Clin44102354083405570108
Oncol.453323540834786118155171183
2019;37(4):269-277.473223540833468100130143178210226259277289324357391415446479513519
63.39402453085357085
Al-Sawaf40372454083405577108140190222240
O,428924540834657
Zhang435824540833875106143181
C,455224540833951
Tandon46162454083325996134172209
M,483824540835366
et491624540833456
al.49842454083314658
Venetoclax505524540833567104138160196228243274305
plus53722454083385490116
obinutuzumab5500245408337769139402554083377496134162200257289327
versus42802554083316586112149175
chlorambucil44672554083316883121142175232270308339354369
plus48482554083395491117
obinutuzumab49772554083377691128165188225254291348380419
for54082554083185576
previously5497255408338599339402654083314784121147162193
untreated41452654083377495116150181202235274
chronic44312654083316889125163178209
lymphocytic465226540831546104142180218250283307322353
leukaemia50172654083154986116149183240254286
(CLL14):53152654083185788119148179196207
follow-up55352654083185539402754083153068119141180219
results41732754083205481119134156184
from43702754083194178136
a4520275408332
multicentre,456527540835795110133148180214252273295329341
open-label,491927540833777113151173189222261296312324
randomised,52572754083205391131169227242268303343355
phase394028540833977109136171
34126285408335
trial.4176285408321435991106119
Lancet431028540833165103135169191
Oncol.451628540834786118155171184
2020;21(9):1188-1200.471528540833469101136148183215230262280292322350381416439470500534570582
64.39402953085367489
Dreger404729540834567101141176197
P.426129540833541
Is431929540831541
There437829540833271106128162
a4557295408332
Role46072954083357389124
for47492954083185677
Cellular48442954083407389104142157189210
Therapy507229540833272107128161200231
in532129540831552
Chronic53912954083407899136175190222
Lymphocytic394030540833160118158196234267301325341373
Leukemia?432830540833165103133167225241273297
Cancer464030540834073111143177198
J.485430540832436
2021;27(4):297-305.490630540833468101132140175208225258275287322356389408440475509521
65.39403153085357186
Tournilhac403931540833266104125164179194232264296
O,434831540834758
van442031540833164101
Gelder45353154083437894133168189
M,473731540835468
Eikema48183154083324777111169201
DJ,50323154083456780
et512531540833456
al.51943154083324760
The526831540833271106
European53873154083336990127167202394032540833169
landscape40233254083144684123149181214253288
on432432540833775
allogeneic44133254083314662100139173211246261293
haematopoeietic472032540833769103161193215251291329365380414437452484
cell5217325408331658095
transplantation532632540832143751131391781942262643940335408322557894132171
in413233540831554
Chronic420733540834078100138177193226
Lymphocytic445433540833160119159199238271305331347379
Leukaemia485433540833267105136170206264280313
between51883354083387598151187223262
2009547133540833469105141
and394034540833272113
2019:407634540833570104136150
a4249345408332
perspective43043454083397799128169206240266283317353
from46803454083184281141
the48443454083226299
Chronic496534540834181103142183199233
Malignancies522034540835690107123164203237277311327364392
Working394035540835998122155174214256
Party42253554083367094121157
of441035540833960
the449935540832263101
EBMT.462835540833472130166177
Bone483435540833678119156
Marrow501935540835691115139178233
Transplant.52803554083345389129158200218253293317332
2023;58(6):621-624.394036540833469103138150186221241274293306342376408428466500532545
66.39403753085357286
Mancikova403837540835385122153167196232263295
V,434537540833543
Smida440037540833288102140171
M.458337540835367
Current46623754083397494115148185206
State48803754083325284104137
of502937540833655
CAR509637540833980115
T-Cell52233754083324991124139153
Therapy538837540833270104124156194224
in394038540831553
Chronic40083854083407899136174189221
Lymphocytic424538540833160118157196234267300325340372
Leukemia.463338540833165103133167225240272286
Int49343854083155374
J5024385408324
Mol506338540835493109
Sci.5187385408333658093
2021;22(11).529538540833469101133141176211228260287302313
67.39403953085367180
Thompson404039540833372110169208235273311
MC,437239540835495108
Harrup45003954083447798120158197
RA,47183954083357892
Coombs483139540834077115174213240
CC,50913954083407891
et520339540833456
al.52793954083324861
Venetoclax53603954083366810614216420123439404054083154779
retreatment4032405408321557798132164186244279317339
of438440540833857
patients44544054083397294109144182203231
with46984054083516689127
chronic48384054083327091128166181213
lymphocytic506540540831546105144183221254287312327359
leukemia54384054083144987117151394041540835772104
after40614154083315075109130
a4208415408331
previous42554154083396195127143181219245
venetoclax-based451641540833266104139162199231247279310331371404431466505
regimen.50374154083215595110167202241254
Blood53074154083355189128167
Adv.549141540834179112121
2022;6(15):4553-4557.394042540833468101136148184203235265283295329362395428450486519551585591
68.39404353085367389
Ahn404943540834179117
IE,41864354083144861
Underbayev426643540834482121156177217250280315347
C,463343540833952
Albitar47054354083415795111133166187
A,491243540834155
et498743540833456
al.50634354083314760
Clonal51424354083405593132164180
evolution534143540833466104120157180195233272
leading39404454083155082121136174213
to417344540832158
ibrutinib42514454083155476114137152190205244
resistance4515445408321558296123146178216249282
in481744540831553
chronic48904454083316990128166181213
lymphocytic512344540831547105145183221254288312328360
leukemia.55034454083154987394045540833064122137169182
Blood.41374554083365290128168181
2017;129(11):1469-1479.433345540833569100130140170200234253285312327339368399435469493524555587620631
69.39404653085367285
Seymour40414654083326899158196234255
JF,43124654083245763
Kipps43914654083355190130156
TJ,45634654083335466
Eichhorst46454654083324779117155193215242265
BF,49264654083356974
et501646540833456
al.50884654083324760
Enduring516446540833270109147168184221260
undetectable54404654083377511414939404754083225588112145184200235
MRD419147540835591137
and434447540833270109
updated446947540833776116148170204243
outcomes47284754083377698129166224259286
in503047540831553
relapsed/refractory50994754083205470102141168203243269288322342364397429453490394048540832157
CLL401948540834174108
after41494854083335379115137
fixed-duration43084854083183568103144168210249271306329345385425
venetoclax-rituximab.475548540833369108145168207241258291324346369386409449482498558592633646
Blood.54244854083365393133174188
2022;140(8):839-850.394049540833468101136148178209245265299317329363397431454490524558571
70.39405053085356984
Shanafelt403650540833269100137169187220235257
TD,43055054083327888
Borah44055054083357293125162
BJ,45795054083355970
Finnes46615054083324683120154180
HD,48535054083448899
et496450540833355
al.50315054083314658
Impact510150540831471109141172196
of530950540833655
ibrutinib53765054083145273111132147184198236
and394051540833269108
idelalisib40615154083155388103135151166191206245
on431951540833775
the44075154083226094
pharmaceutical451451540833977109130188220252286323346361393425441
cost49675154083316895118
of509751540833857
treating51675154083214276108130145182221
chronic54015154083316990127165180212
lymphocytic394052540831547105144183221254287312328359
leukemia43185254083155088118152210225257
at459452540833153
the46665254083226095
individual47805254083145291106139155193231263279
and507752540833270109
societal52055254083266497112147169202217
levels.54415254083155082116132158172
J3940535408324
Oncol397953540834786118155171
Pract.41655354083365689121146159
2015;11(3):252-258.433953540833468100130141171199214247265276312347380400431466500513
71.39405453085367183
Hilal40395454083445974107122
T,417754540833241
Betcher42345454083357093123161196218
JA,44675454083246478
Leis45615454083316681107
JF.46835454083255864
Economic476354540833264101139177236251283
Impact506154540831573112145177201
of527854540833757
Oral535054540834769102117
Therapies54835454083337210739405554083215392107142168
for41215554083185576
Chronic42105554083407798135173188219
Lymphocytic444255540833159117156194232264298322337369
Leukemia-the482355540833265103132166224239270292314352387
Burden52235554083357293131165203
of543955540833756
Novelty.55075554083458339405654083326682104138148
Curr41035654083407698119
Hematol423856540834479137169191228244
Malig449756540835487102117156
Rep.466856540833671110122
2018;13(4):237-243.480656540833468100131143173203221254272283319353385404435467499512
72.39405753085367390
Davids405257540834679111128168195
MS,426957540835589102
Chatterjee439357540834079112135160195217234269306
A,472157540834156
Ravelo479957540833569102137153192
A,501357540834257
et509257540833457
al.51715754083324862
Cost-Effectiveness525557540834078106130150185205224260293318335394058540833166104139167193
of414758540833757
a4218585408331
12-Month42635854083346485141180218240279
Fixed45555854083334879113153
Duration472258540834584105138160176214253
of498958540833756
Venetoclax505958540833669107142165202235250283315
in538858540831452
Combination54545854083407713539405954083385492124146162200238
with41925954083506588126
Obinutuzumab433259540834686102140177200238267305363395434
in478059540831552
First-Line4846595408332476896119139172188226261
Chronic51205954083407899136174190222
Lymphocytic53555954083316011815719623439406054083316489104136
Leukemia408960540833165102132166223238270
in437360540831452
the44386054083215994
United45456054083438196118152191
States.47496054083325386107141167181
Blood.49446054083345088126165179
2019;134(Supplement_1):4741.51366054083346799129142172202237256288325363403419453394061540835793132154192225240252287320351382392
73.39406253085367186
Patel40386254083356687121136
K,418662540833549
Isufi4247625408315417795112
I,437162540831527
Kothari44106254083357293131163183198
S,462162540833244
et467862540833455
al.47466254083314659
Cost-Effectiveness481762540834076102125144178197215249281305320352386423457484510
of533962540833756
First-Line5408625408332466794116135168183394063540833771
Ibrutinib40226354083155373110132146183197235
versus42696354083316484110146172
Third-Line44526354083327085105142163195210246280
in474463540831451
Patients48066354083356686101134171192219
with50366354083506586123
Untreated517163540834379100120153184205237276
Chronic5458635408339769613239406454083385385
Lymphocytic404064540833160118157196234267300325341373
Leukemia.442864540833165103133167225240272286
Blood.47296454083355189128168181
2020;136(17):1946-1955.492564540833468101135148178208243262293323342354384414450486509540570605637649
74.39406553085366985
Simkovic404665540833348106137174207223255
M,432265540835569
Vodarek441165540833673113145167201232
P,466465540833540
Motyckova472565540835593116150182212250282316
M,506265540835468
et515165540833457
al.52296554083324760
Rituximab,53106554083365274113144160218251291303
Cyclophosphamide39406654083406899115153192231269296335373405463478517552
and451266540833270109
Dexamethasone464166540834580112145202238260298330357395434469
(RCD)51296654083195596141159
Chemoimmunotherapy530866540834077112170209224282394067540835794131168190227262282315353384
for43366754083185576
Relapsed44256754083346984116154180214253
Chronic46916754083397697133171186217
Lymphocytic492067540833159117155193231263296320335366
Leukaemia.529867540833165102131164198255270301314
Eur39406854083336990
J4046685408324
Clin40856854083405570108
Invest.42086854083155384119146169182
2021;51(4):e13421.440568540833569101133141176207222255273285319349379414447478488
75.39406953085367186
Smolej404769540833391129145181196
L,426469540833145
Špaček433069540833271105137171201
M,455269540835568
Pospíšilová,46416954083357299139154182197213251284317330
et499169540833557
al.50696954083324760
Doporučení515069540834685125164186224256290329344
pro55156954083386098
diagnostiku39407054083385385124162201227250266296334
a4292705408332
léčbu43427054083154982121159
chronické45197054083316991128166181213243278
lymfocytární481570540831446105124161194228252285306345360
leukemie51937054083155087118152210225259
2021.547170540833468101132141
Transfuze39407154083335083121147167206235269
Hematol.422471540834580137170192229244257
dnes449771540833876111138
2021;27(1):91-106.465071540833468101133141176209225257271283318350369400431467480
76.39407253085367086
Eichhorst40417254083334779117155194215243266
B,432272540833548
Niemann43857254083456094152185223261
CU,46617254083408494
Kater47717254083346890124145
AP,49317254083417681
et502772540833456
al.50987254083324760
First-Line5173725408333486996119139172187225260
Venetoclax54487254083366910714239407354083226195111144177
Combinations413973540834180140181197237270293309349389416
in457773540831554
Chronic465373540834181103141181197231
Lymphocytic490573540833362123164204244278313339355388
Leukemia.531573540833268107138174234250283297
N3940745408345
Engl400074540833370109125
J4140745408324
Med.418074540835489129142
2023;388(19):1739-1754.433774540833468101136147182217252271303333351363393422456490513544573606641654
77.39407553085367281
Mato403975540835487109146
AR,42037554083417791
Woyach431275540835794125158190228
JA,45587554083246479
Brown46557554083355694145183
JR,48577554083246074
et494975540833456
al.50237554083324860
Pirtobrutinib5102755408335497095132172193231254269307322361
after54827554083315075109130
a3940765408332
Covalent398776540834077109142158192231252
BTK425576540833569105
Inhibitor43767654083145290106145160183220241
in463376540831552
Chronic47017654083407899136175190222
Lymphocytic493876540833260119158196235267301326341373
Leukemia.532776540833165103133167225240272286
N3940775408345
Engl400077540833370109125
J4140775408324
Med.418077540835489129142
2023;389(1):33-44.433777540833468101136147182217251270302316328363396418455492504